New drug combo aims to overcome resistance in hard-to-treat lung cancer
NCT ID NCT04895579
First seen Nov 18, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This early-phase study tested whether adding the drug copanlisib to the standard immunotherapy durvalumab could help patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study included 11 people who had already received chemotherapy and radiation. The main goal was to see if the combination was safe and tolerable, and to check if it could improve the immune system's ability to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.